AGIOS PHARMACEUTICALS ($AGIO) posted quarterly earnings results for Q4 2025 on Thursday, February 12th. The company reported earnings of -$1.85 per share, beating estimates of -$1.99 by $0.14. The company also reported revenue of $19,970,000, beating estimates of $12,253,943 by $7,716,057.
You can see Quiver Quantitative's $AGIO stock page to track data on insider trading, hedge fund activity, congressional trading, and more.
AGIOS PHARMACEUTICALS Insider Trading Activity
AGIOS PHARMACEUTICALS insiders have traded $AGIO stock on the open market 15 times in the past 6 months. Of those trades, 0 have been purchases and 15 have been sales.
Here’s a breakdown of recent trading of $AGIO stock by insiders over the last 6 months:
- BRIAN GOFF (Chief Executive Officer) has made 0 purchases and 2 sales selling 18,703 shares for an estimated $506,664.
- SARAH GHEUENS (Chief Medical Officer) has made 0 purchases and 4 sales selling 8,888 shares for an estimated $340,649.
- THEODORE JAMES JR. WASHBURN (Principal Accounting Officer) sold 8,546 shares for an estimated $315,091
- CECILIA JONES (Chief Financial Officer) has made 0 purchases and 2 sales selling 6,583 shares for an estimated $213,675.
- TSVETA MILANOVA (Chief Commercial Officer) has made 0 purchases and 2 sales selling 5,804 shares for an estimated $157,029.
- JAMES WILLIAM BURNS (Chief Legal Officer) sold 2,932 shares for an estimated $79,427
- DAVID SCADDEN has made 0 purchases and 3 sales selling 600 shares for an estimated $24,968.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
AGIOS PHARMACEUTICALS Hedge Fund Activity
We have seen 112 institutional investors add shares of AGIOS PHARMACEUTICALS stock to their portfolio, and 126 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- WELLINGTON MANAGEMENT GROUP LLP added 2,049,287 shares (+485.5%) to their portfolio in Q3 2025, for an estimated $82,258,380
- PARADIGM BIOCAPITAL ADVISORS LP added 1,531,044 shares (+134.0%) to their portfolio in Q3 2025, for an estimated $61,456,106
- FISHER ASSET MANAGEMENT, LLC removed 870,145 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $23,685,346
- DEUTSCHE BANK AG\ removed 803,859 shares (-86.7%) from their portfolio in Q4 2025, for an estimated $21,881,041
- TCG CROSSOVER MANAGEMENT, LLC added 733,038 shares (+105.2%) to their portfolio in Q3 2025, for an estimated $29,424,145
- CAPITAL INTERNATIONAL INVESTORS added 703,865 shares (+inf%) to their portfolio in Q4 2025, for an estimated $19,159,205
- PRICE T ROWE ASSOCIATES INC /MD/ removed 617,311 shares (-27.1%) from their portfolio in Q3 2025, for an estimated $24,778,863
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
AGIOS PHARMACEUTICALS Congressional Stock Trading
Members of Congress have traded $AGIO stock 1 times in the past 6 months. Of those trades, 1 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $AGIO stock by members of Congress over the last 6 months:
- REPRESENTATIVE GILBERT RAY CISNEROS, JR. purchased up to $15,000 on 12/11.
To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard.
AGIOS PHARMACEUTICALS Analyst Ratings
Wall Street analysts have issued reports on $AGIO in the last several months. We have seen 5 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Leerink Partners issued a "Outperform" rating on 12/26/2025
- B of A Securities issued a "Buy" rating on 12/24/2025
- Citigroup issued a "Buy" rating on 11/26/2025
- Truist Securities issued a "Buy" rating on 11/24/2025
- HC Wainwright & Co. issued a "Buy" rating on 11/20/2025
To track analyst ratings and price targets for AGIOS PHARMACEUTICALS, check out Quiver Quantitative's $AGIO forecast page.
AGIOS PHARMACEUTICALS Price Targets
Multiple analysts have issued price targets for $AGIO recently. We have seen 8 analysts offer price targets for $AGIO in the last 6 months, with a median target of $36.0.
Here are some recent targets:
- Tessa Romero from JP Morgan set a target price of $25.0 on 01/06/2026
- Andrew Berens from Leerink Partners set a target price of $40.0 on 12/26/2025
- Greg Harrison from B of A Securities set a target price of $34.0 on 12/24/2025
- Gregory Renza from Truist Securities set a target price of $38.0 on 12/24/2025
- Emily Bodnar from HC Wainwright & Co. set a target price of $62.0 on 12/24/2025
- Samantha Semenkow from Citigroup set a target price of $38.0 on 11/26/2025
- Salveen Richter from Goldman Sachs set a target price of $25.0 on 11/20/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
